Joseph Gadzia

Nov 1, 2024 | jitc.bmj.com | Etan Marks |Robert Cook |Sonia Morgan-Linnell |Joseph Gadzia

Abstract Background Currently, FDA-approved adjuvant immunotherapies are not approved for patients with stage IB–IIA cutaneous melanoma (CM), and this group is not recommended for asymptomatic surveillance imaging.1 However, patients with stage IB-IIA CM have up to 20–38% recurrence rates and account for approximately one-quarter of all patients with CM.2 3 Thus, additional methods to identify which patients in this group are at the highest risk for recurrence are needed so that clinicians...